Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide
Inclusion Criteria:
- Patients with multiple myeloma receiving a chemotherapy protocol including
thalidomide or lenalidomide
Exclusion Criteria:
- Patients involved in an interventional clinical trial
Type of Study:
Observational
Study Design:
Observational Model: Cohort
Outcome Measure:
Disease history and VETD risk factors. Chemotherapy protocol for multiple myeloma. Therapeutic used for VETD prevention (LWMH, anticoagulants, antiplatelets or none)
Outcome Time Frame:
4 months
Safety Issue:
Yes
Authority:
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
Study ID:
Melisse study
NCT ID:
NCT01268774
Start Date:
February 2009
Completion Date:
July 2011
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|
